TY 2025 Form 990

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
(1) MARGARET E SMITH...................................................................... CEO & DIRECTOR	40.00 .................	X	X			501,560	29,619
(2) HENRY MCCANCE...................................................................... CHAIR & DIRECTOR	5.00 .................	X	X			0	0
(3) PHYLLIS RAPPAPORT...................................................................... TREASURER & DIRECTOR	5.00 .................	X	X			0	0
(4) TIMOTHY ARMOUR...................................................................... DIRECTOR	3.00 .................	X				0	0
(5) RICHARD BIRNBAUM...................................................................... DIRECTOR	4.00 .................	X				0	0
(6) BRITTANY BOWLEN...................................................................... DIRECTOR (AS OF 5/25)	3.00 .................	X				0	0
(7) MARK FAGGIANO...................................................................... DIRECTOR	3.00 .................	X				0	0
(8) MARY GREENHILL CAGLIERO...................................................................... DIRECTOR	3.00 .................	X				0	0
(9) KUMAR MAHADEVA...................................................................... DIRECTOR	3.00 .................	X				0	0
(10) JACQUELINE MORBY...................................................................... DIRECTOR	4.00 .................	X				0	0
(11) CHRISTINE VILLAS-BOAS...................................................................... DIRECTOR (AS OF 3/25)	3.00 .................	X				0	0
(12) JOSEPHINE ANTONELLIS...................................................................... CFO	30.00 .................		X			225,192	8,002
(13) LAUREL LYLE...................................................................... SECRETARY & VP, BOARD RELATIONS & DEV.	30.00 .................		X			133,686	4,655
(14) KATHARINE HERMAN...................................................................... EVP DEVELOPMENT	40.00 .................			X		458,522	31,035
(15) BARBARA CHAMBERS...................................................................... EVP MARKETING & COMM.	40.00 .................			X		303,031	24,478
(16) DANIEL HARPER...................................................................... VP DEVELOPMENT	40.00 .................				X	220,918	14,361
(17) LISA RAND...................................................................... VP MARKETING & COMM.	40.00 .................				X	217,091	19,494

- TIN:

SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2025

Open to Public
Inspection

Name of the organization

ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number

52-2396428

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E (Form 990).)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An agricultural research organization described in 170(b)(1)(A)(ix) operated in conjunction with a land-grant college or university or a non-land grant college of agriculture. See instructions. Enter the name, city, and state of the college or university:

An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

Type I. A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. You must complete Part IV, Sections A and B.

Type II. A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). You must complete Part IV, Sections A and C.

Type III functionally integrated. A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). You must complete Part IV, Sections A, D, and E.

Type III non-functionally integrated. A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization must generally satisfy a distribution requirement and an attentiveness requirement (see instructions). You must complete Part IV, Sections A and D, and Part V.

Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

Enter the number of supported organizations ...........................

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
(i) Name of supported organization	(ii) EIN	Yes	No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)


Total

For Paperwork Reduction Act Notice, see the Instructions for
Form 990 or 990-EZ.

Cat. No. 11285F

Schedule A (Form 990) 2025

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization failed to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2021	(b) 2022	(c) 2023	(d) 2024	(e) 2025	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") ..	26,547,838	32,354,655	36,697,205	30,788,755	55,362,142	181,750,595
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf ....
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3	26,547,838	32,354,655	36,697,205	30,788,755	55,362,142	181,750,595
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) ..						14,368,215
6	Public support. Subtract line 5 from line 4.						167,382,380

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2021	(b) 2022	(c) 2023	(d) 2024	(e) 2025	(f) Total
7	Amounts from line 4..	26,547,838	32,354,655	36,697,205	30,788,755	55,362,142	181,750,595
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...	4,497	93,408	992,260	997,714	1,334,483	3,422,362
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)..
11	Total support. Add lines 7 through 10						185,172,957

Gross receipts from related activities, etc. (see instructions) ..................

397,698

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here ........................................

Section C. Computation of Public Support Percentage

Public support percentage for 2025 (line 6, column (f) divided by line 11, column (f)) .........

90.390 %

Public support percentage for 2024 Schedule A, Part II, line 14 ...............

86.450 %

16a

33 1/3% support test—2025. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization .......................

33 1/3% support test—2024. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization .....................

17a

10%-facts-and-circumstances test—2025. If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............

10%-facts-and-circumstances test—2024. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions .....................................................

Schedule A (Form 990) 2025

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2021	(b) 2022	(c) 2023	(d) 2024	(e) 2025	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose
3	Gross receipts from activities that are not an unrelated trade or business under section 513 .....
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge
6	Total. Add lines 1 through 5
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2021	(b) 2022	(c) 2023	(d) 2024	(e) 2025	(f) Total
9	Amounts from line 6
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975
c	Add lines 10a and 10b
11	Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

Section C. Computation of Public Support Percentage

Public support percentage for 2025 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2024 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2025 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2024 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests-2025. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization .......

33 1/3 % support tests—2024. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization .....

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ....

Schedule A (Form 990) 2025

Page 4

Part IV

Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, of Part I, complete Sections A and B. If you checked box 12b, of Part I, complete Sections A and C. If you checked box 12c, of Part I, complete Sections A, D, and E. If you checked box12d, of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

Yes

Are all of the organization’s supported organizations listed by name in the organization’s governing documents?
If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose,
describe the designation. If historic and continuing relationship, explain.

Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).

Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.

Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.

Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.

Was any supported organization not organized in the United States ("foreign supported organization")? If “Yes” and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.

Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If “Yes,” describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.

Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If “Yes,” explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.

Did the organization add, substitute, or remove any supported organizations during the tax year? If “Yes,” answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).

Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?

Substitutions only. Was the substitution the result of an event beyond the organization's control?

Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization’s supported organizations? If “Yes,” provide detail in Part VI.

Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If “Yes,” complete Part I of Schedule L (Form 990) .

Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? If “Yes,” complete Part I of Schedule L (Form 990).

Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If “Yes,” provide detail in Part VI.

Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If “Yes,” provide detail in Part VI.

Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If “Yes,” provide detail in Part VI.

10a

Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If “Yes,” answer line 10b below.

10a

Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).

10b

Schedule A (Form 990) 2025

Page 5

Part IV

Supporting Organizations (continued)

Yes

Has the organization accepted a gift or contribution from any of the following persons?

A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?

11a

A family member of a person described on 11a above?

11b

A 35% controlled entity of a person described on line 11a or 11b above? If “Yes” to 11a, 11b, or 11c, provide detail in Part VI.

11c

Section B. Type I Supporting Organizations

Yes

Did the officers, directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization’s directors or trustees at all times during the tax year? If “No,” describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization’s activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.

Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If “Yes,” explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.

Section C. Type II Supporting Organizations

Yes

Were a majority of the organization’s directors or trustees during the tax year also a majority of the directors or trustees of each of the organization’s supported organization(s)? If “No,” describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).

Section D. All Type III Supporting Organizations

Yes

Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization’s tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization’s governing documents in effect on the date of notification, to the extent not previously provided?

Were any of the organization’s officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).

By reason of the relationship described in line 2 above, did the organization’s supported organizations have a significant voice in the organization’s investment policies and in directing the use of the organization’s income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization’s supported organizations played in this regard.

Section E. Type III Functionally-Integrated Supporting Organizations

Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):

The organization satisfied the Activities Test. Complete line 2 below.

The organization is the parent of each of its supported organizations. Complete line 3 below.

The organization supported a governmental supported organization. Describe in Part VI how you supported a governmental supported organization (see instructions).

Activities Test. Answer lines 2a and 2b below.

Yes

Did substantially all of the organization’s activities during the tax year directly further the exempt purposes of its supported organization(s)? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to each of its supported organizations, and how the organization determined that these activities constituted substantially all of its activities.

Did the activities described on line 2a, above, constitute activities that, but for the organization’s involvement, one or more of the organization’s supported organization(s) would have been engaged in? If “Yes,” explain in Part VI the reasons for the organization’s position that its supported organization(s) would have engaged in these activities but for the organization’s involvement.

Parent of Supported Organizations. Answer lines 3a, 3b, and 3c below.

Are the organization and its supported organization(s) part of an integrated system (for example, a hospital system)? If “Yes,” provide details in Part VI.

Did the organization direct the policies, programs, and activities of each of its supported organizations? If "Yes," describe in Part VI the role played by the organization in this regard.

Did the organization have the power to regularly appoint or elect (and remove) a majority of the officers, directors, or trustees of each of the supported organizations?If "Yes" or "No", provide details in Part VI.

Schedule A (Form 990) 2025

Page 6

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions. All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

	Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1
2	Recoveries of prior-year distributions	2
3	Other gross income (see instructions)	3
4	Add lines 1 through 3	4
5	Depreciation and depletion	5
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6
7	Other expenses (see instructions)	7
8	Adjusted Net Income (subtract lines 5, 6 and 7 from line 4)	8

	Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):	1
a	Average monthly value of securities	1a
b	Average monthly cash balances	1b
c	Fair market value of other non-exempt-use assets	1c
d	Total (add lines 1a, 1b, and 1c)	1d
e	Discount claimed for blockage or other factors (explain in detail in Part VI):
2	Acquisition indebtedness applicable to non-exempt use assets	2
3	Subtract line 2 from line 1d	3
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5
6	Multiply line 5 by 0.035	6
7	Recoveries of prior-year distributions	7
8	Minimum Asset Amount (add line 7 to line 6)	8

	Section C - Distributable Amount		Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1
2	Enter 85% of line 1	2
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3
4	Enter greater of line 2 or line 3	4
5	Income tax imposed in prior year	5
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6

Check here if the current year is the organization's first as a non-functionally- integrated Type III supporting organization (see instructions)

Schedule A (Form 990) 2025

Page 7

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations(continued)

Section D - Distributions		Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes	1
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	3
4 Amounts paid to acquire exempt-use assets	4
5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI)	5
6Total annual distributions. Add lines 1 through 5.	6
7 Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions	7
8 Distributable amount for 2025 from Section C, line 6	8
9 Line 7 amount divided by Line 8 amount	9

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2025	(iii) Distributable Amount for 2025
1 Distributable amount for 2025 from Section C, line 6
2 Underdistributions, if any, for years prior to 2025 (reasonable cause required-- explain in Part VI). See instructions.
3 Excess distributions carryover, if any, to 2025:
a From 2020.......
b From 2021.......
c From 2022.......
d From 2023.......
e From 2024.......
fTotal of lines 3a through e
g Applied to underdistributions of prior years
h Applied to 2025 distributable amount
i Carryover from 2020 not applied (see instructions)
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.
4Distributions for 2025 from Section D, line 6:
$
a Applied to underdistributions of prior years
b Applied to 2025 distributable amount
c Remainder. Subtract lines 4a and 4b from line 4.
5 Remaining underdistributions for years prior to 2025, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions.
6 Remaining underdistributions for 2025. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions.
7 Excess distributions carryover to 2026. Add lines 3j and 4c.
8 Breakdown of line 7:
a Excess from 2021.....
b Excess from 2022.....
c Excess from 2023.....
d Excess from 2024.....
e Excess from 2025.....

Schedule A (Form 990) (2025)

Schedule A (Form 990) 2025

Page 8

Part VI

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a, 3b, and 3c; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5 and 7; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Return Reference	Explanation

Schedule A (Form 990) 2025

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990)
(Rev. January 2025)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

Name of the organization

ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number

52-2396428

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling $5,000 or more (in money or other property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

Special Rules

For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990 or 990-EZ), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I, II, and III.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions exclusively for religious, charitable, etc., purposes, but no such contributions totaled more than $1,000. If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Don't complete any of the parts unless the General Rule applies to this organization because it received nonexclusively religious, charitable, etc., contributions totaling $5,000 or more during the year ......... $

Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ
or on its Form 990PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990) (Rev. 1-2025)

Schedule B (Form 990) (Rev. 2025) Page 2

Name of organization ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Part I	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	,	$ RESTRICTED	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
Schedule B (Form 990) (Rev. 1-2025)

Schedule B (Form 990) (Rev. 1-2025)

Page 3

Name of organization ALZHEIMER'S DISEASE RESEARCH FOUNDATION		Employer identification number 52-2396428

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
Schedule B (Form 990) (Rev. 1-2025)

Schedule B (Form 990) (Rev. 1-2025)

Page 4


Name of organization ALZHEIMER'S DISEASE RESEARCH FOUNDATION			Employer identification number 52-2396428
Part III Exclusively religious, charitable, etc., contributions to organizations described in section 501(c) (7), (8), or (10) that total more than $1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of $1,000 or less for the year. (Enter this information once. See instructions.) $ Use duplicate copies of Part III if additional space is needed.

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990) (Rev. 1-2025)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization

ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number

52-2396428

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate value of contributions to (during year)
3	Aggregate value of grants from (during year)
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization’s property, subject to the organization’s exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements.
Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements ......................	2a
b	Total acreage restricted by conservation easements ....................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after July 25, 2006, and not on a historic structure listed in the National Register ...	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the
tax year

Number of states where property subject to conservation easement is located

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ............

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year

Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
$

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .............................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenue included on Form 990, Part VIII, line 1 ......................... $

(ii)

Assets included in Form 990, Part X ............................... $

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under FASB ASC 958 relating to these items:

Revenue included on Form 990, Part VIII, line 1 .......................... $

Assets included in Form 990, Part X ............................... $

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) (Rev. 1-2025)

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?...

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No


b	If "Yes," explain the arrangement in Part XIII and complete the following table:		Amount
c	Beginning balance .............................	1c
d	Additions during the year ............................	1d
e	Distributions during the year ..........................	1e
f	Ending balance ................................	1f

Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ...

Yes No

If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ....

Part V

Endowment Funds.
Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

		(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back

1a	Beginning of year balance ....
b	Contributions ...
c	Net investment earnings, gains, and losses
d	Grants or scholarships ...
e	Other expenditures for facilities and programs ...
f	Administrative expenses ....
g	End of year balance ......

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment

Permanent endowment

Term endowment

The percentages on lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) Unrelated organizations .................

3a(i)

(ii) Related organizations .................

3a(ii)

If "Yes" on 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property		(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value

1a	Land .....
b	Buildings ....
c	Leasehold improvements	8,688	3,620	5,068
d	Equipment ....
e	Other .....
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).)..				5,068

Schedule D (Form 990) (Rev. 1-2025)

Page 3

Part VII

Investments - Other Securities.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives.........
(2) Closely-held equity interests........
(3)Other
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)

Part VIII

Investments - Program Related. Complete if the organization answered 'Yes' on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description				(b) Book value

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........

Part X

Other Liabilities.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1.(a) Description of liability	(b) Book value
(1) Federal income taxes
ACCRUED PAYROLL AND RELATED	739,590
LEASE PAYABLE	142,130







Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)	881,720
2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII

Schedule D (Form 990) (Rev. 1-2025)

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......			1	56,426,807
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains (losses) on investments ....	2a	-179,122
b	Donated services and use of facilities .........	2b
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ...........	2d
e	Add lines 2a through 2d .....................			2e	-179,122
3	Subtract line 2e from line 1..................			3	56,605,929
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a	53,906
b	Other (Describe in Part XIII.) ...........	4b
c	Add lines 4a and 4b....................			4c	53,906
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......			5	56,659,835

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........			1	46,178,770
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities .........	2a
b	Prior year adjustments ............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ...........	2d
e	Add lines 2a through 2d....................			2e	0
3	Subtract line 2e from line 1...................			3	46,178,770
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a	53,906
b	Other (Describe in Part XIII.) ...........	4b
c	Add lines 4a and 4b.....................			4c	53,906
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......			5	46,232,676

Part XIII

Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference

Explanation

PART X, LINE 2:

THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVELS. THE ORGANIZATION ANNUALLY FILES IRS FORM 990 RETURNS OF ORGANIZATIONS EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS.

Schedule D (Form 990) (Rev. 1-2025)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE F(Form 990)
(Rev. January 2025)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990, Part IV, line 14b, 15, or 16.Attach to Form 990.Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization
ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number

52-2396428

Part I

General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

For grantmakers. Does the organization maintain records to substantiate the amount of its grants and

other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used

to award the grants or assistance? . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.

Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region		(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in the region	(f) Total expenditures for and investments in the region
	EUROPE (INCLUDING ICELAND & GREENLAND) - BELGIUM, FINLAND, GERMANY, NETHERL	0	0	GRANTS AWARDED	ALZHEIMER'S DISEASE RESEARCH	2,488,952
	MIDDLE EAST AND NORTH AFRICA - ISRAEL	0	0	GRANTS AWARDED	ALZHEIMER'S DISEASE RESEARCH	7,763
	EAST ASIA AND THE PACIFIC - AUSTRALIA, SINGAPORE	0	0	GRANTS AWARDED	ALZHEIMER'S DISEASE RESEARCH	402,388
	NORTH AMERICA - CANADA	0	0	GRANTS AWARDED	ALZHEIMER'S DISEASE RESEARCH	612,041













3a	Sub-total ....	0	0			3,511,144
b	Total from continuation sheets to Part I ...	0	0			0
c	Totals (add lines 3a and 3b)	0	0			3,511,144

For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) (Rev. 1-2025)

Schedule F (Form 990) (Rev. 1-2025)

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement
AUSTRALIA	DEVELOPING BRAIN-TARGETED AAVS USING HUMAN BLOOD-BRAIN BARRIER RECEPTORS	201,138	WIRE TRANSFER
BELGIUM	BRAIN-PENETRANT COMPLEMENT BLOCKING VHHS TO REDUCE NEURO-INFLAMMATION IN ALZHEIMER'S DISEASE	166,750	WIRE TRANSFER
BELGIUM	PRECLINICAL ANALYSIS OF SYNAPTOGYRIN-3 OLIGONUCLEOTIDES TO TARGET TAUOPATHY	201,250	WIRE TRANSFER
BELGIUM	BAC: THE 100-PLUS STUDY BRAIN COHORT: IDENTIFYING MOLECULAR DETERMINANTS OF RESISTANCE, RESILIENCE AND EARLY COGNITIVE DECLINE IN THE OLDEST-OLD	287,500	WIRE TRANSFER
CANADA	UNRAVELLING PRECISION HORMONE THERAPY USING MENOPAUSE AND HORMONE THERAPY TYPE ACROSS APOE GENOTYPE	201,250	WIRE TRANSFER
CANADA	ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER	7,763	WIRE TRANSFER
CANADA	ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER	47,115	WIRE TRANSFER
CANADA	REFERENCE INTERVALS FOR PLASMA P-TAU-217 IN THE CANADIAN POPULATION	57,500	WIRE TRANSFER
CANADA	APOE CONSORTIUM: APOE AND IMMUNE CHECKPOINT REGULATION DURING AGING	298,414	WIRE TRANSFER
FINLAND	NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE	23,000	WIRE TRANSFER
GERMANY	CHARACTERIZATION OF THE LONGITUDINAL TRAJECTORIES OF THE SYNAPTIC BLOOD MARKER -SYNUCLEIN DURING AD PATHOGENESIS AND IMPROVEMENT OF THE MEASUREMENT PROCEDURE	111,780	WIRE TRANSFER
GERMANY	CHARACTERIZATION OF THE LONGITUDINAL TRAJECTORIES OF THE SYNAPTIC BLOOD MARKER -SYNUCLEIN DURING AD PATHOGENESIS AND IMPROVEMENT OF THE MEASUREMENT PROCEDURE	34,500	WIRE TRANSFER
ISRAEL	ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER	7,763	WIRE TRANSFER
NETHERLANDS	UNDERSTANDING THE DYNAMIC LIPID-IMMUNOMETABOLOME OF PROTECTIVE AND RISK ALZHEIMER MICROGLIA	201,250	WIRE TRANSFER
NORWAY	ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE	108,000	WIRE TRANSFER
SINGAPORE	MULTIDIMENSIONAL PROFILING OF TREM2-MUTATED OR APOE4-MUTATED MICROGLIA IN HUMAN BRAIN ORGANOIDS TO UNDERSTAND DYSREGULATED MICROGLIA NEURONAL CROSSTALK IN AD	201,250	WIRE TRANSFER
SWEDEN	ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE	90,620	WIRE TRANSFER
SWEDEN	CHARACTERIZATION OF TAU PATHOLOGY HETEROGENEITY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM	201,250	WIRE TRANSFER
SWEDEN	UNDERSTANDING AMYLOID PATHOLOGY - MULTIOMIC ACTIVITY IMAGING OF PLAQUE FORMATION DYNAMICS (AMYMAP)	84,004	WIRE TRANSFER
UNITED KINGDOM	BRAIN-PENETRANT COMPLEMENT BLOCKING VHHS TO REDUCE NEURO-INFLAMMATION IN ALZHEIMER'S DISEASE	33,638	WIRE TRANSFER
UNITED KINGDOM	SCALING THE DIVIDE IN ALZHEIMER'S DISEASE: AN INTEGRATED MOLECULAR, CELLULAR AND NETWORK-LEVEL STUDY	201,199	WIRE TRANSFER
UNITED KINGDOM	USING LONG-READ SEQUENCING TO INVESTIGATE THE MAPT LOCUS AND TRANSCRIPTS IN NEURODEGENERATION	201,250	WIRE TRANSFER
UNITED KINGDOM	CELLULAR VULNERABILITY TO PATHOLOGICAL TAU PROTEIN ACCUMULATION IN ALZHEIMER'S DISEASE	229,770	WIRE TRANSFER
UNITED KINGDOM	INVESTIGATING THE SERIAL PATHOLOGIES RELATED TO PLASMA BIOMARKERS IN NLFTAUM/H MICE; A NEW MOUSE MODEL FEATURING NEUROFIBRILLARY TANGLES AS A RESULT OF RISING AMYLOID WITHOUT MAPT MUTATIONS	197,083	WIRE TRANSFER
UNITED KINGDOM	UNDERSTANDING AMYLOID PATHOLOGY - MULTIOMIC ACTIVITY IMAGING OF PLAQUE FORMATION DYNAMICS (AMYMAP)	116,107	WIRE TRANSFER

2	Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .......	19
3	Enter total number of other organizations or entities .......................	0

Schedule F (Form 990) (Rev. 1-2025)

Schedule F (Form 990) (Rev. 1-2025)Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of noncash assistance	(g) Description of noncash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) (Rev. 1-2025)

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) (Rev. 1-2025)

Page 5

Part V

Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

ReturnReference	Explanation
PART I, LINE 2:	THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED.

Schedule F (Form 990) (Rev. 1-2025)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE G (Form 990)
(Rev. January 2025)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding
Fundraising or Gaming Activities

Complete if the organization answered "Yes" on Form 990, Part IV, lines 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a. Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization
ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number

52-2396428

Part I

Fundraising Activities.Complete if the organization answered "Yes" on Form 990, Part IV, line 17.

Form 990-EZ filers are not required to complete this part.

Indicate whether the organization raised funds through any of the following activities. Check all that apply.

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and email solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations

Did the organization have a written or oral agreement with any individual (including officers, directors, trustees

or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

YesNo

If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)	(iii) Did fundraiser have custody or control of contributions?
	Yes	No










Total . . . . . . . . . . . . . . . . . . . .

List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 50083H

Schedule G (Form 990) (Rev. 1-2025)

Page 2

Part II

Fundraising Events. Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

		(a) Event #1 FISHER ISLAND GOLF (event type)	(b) Event #2 (event type)	(c) Other events (total number)	(d) Total events (add col. (a) through col. (c))
1	Gross receipts . . . . .	430,640			430,640
2	Less: Contributions . . . .	321,940			321,940
3	Gross income (line 1 minus line 2) . . . . . .	108,700			108,700

4	Cash prizes . . . . .
5	Noncash prizes . . . .
6	Rent/facility costs . . . .	62,400	62,400
7	Food and beverages . . .	7,664	7,664
8	Entertainment . . . .
9	Other direct expenses . . .	25,288	25,288
10	Direct expense summary. Add lines 4 through 9 in column (d) . . . . . . . . . .		95,352
11	Net income summary. Subtract line 10 from line 3, column (d). . . . . . . . . .		13,348

Part III

Gaming. Complete if the organization answered "Yes" on Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

		(a) Bingo	(b) Pull tabs/Instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col.(a) through col.(c))
1	Gross revenue . . . . .

2	Cash prizes . . . . .
3	Noncash prizes . . . .
4	Rent/facility costs . . . .
5	Other direct expenses . . .

Volunteer labor . . . .

	Yes %
	No

	Yes %
	No

	Yes %
	No

Direct expense summary. Add lines 2 through 5 in column (d) . . . . . . . . . .

Net gaming income summary. Subtract line 7 from line 1, column (d). . . . . . . . .

Enter the state(s) in which the organization conducts gaming activities:

Is the organization licensed to conduct gaming activities in each of these states? . . . . . . . .

YesNo

If "No," explain:

10a

Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? . . .

YesNo

If "Yes," explain:

Schedule G (Form 990) (Rev. 1-2025)

Page 3

Does the organization conduct gaming activities with nonmembers? . . . . . . . . . . .

YesNo

Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity

formed to administer charitable gaming? . . . . . . . . . . . . . . . . .

YesNo

Indicate the percentage of gaming activity conducted in:

The organization's facility . . . . . . . . . . . . . . . . . .

13a

An outside facility . . . . . . . . . . . . . . . . . . . .

13b

Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name

Address

15a

Does the organization have a contract with a third party from whom the organization receives gaming

revenue? . . . . . . . . . . . . . . . . . . . . . . . .

YesNo

If "Yes," enter the amount of gaming revenue received by the organization $ and the

amount of gaming revenue retained by the third party $ .

If "Yes," enter name and address of the third party:

Name

Address

Gaming manager information:

Name

Gaming manager compensation $

Description of services provided

Director/officer Employee Independent contractor

Mandatory distributions:

Is the organization required under state law to make charitable distributions from the gaming proceeds to

retain the state gaming license? . . . . . . . . . . . . . . . . . . .

YesNo

Enter the amount of distributions required under state law distributed to other exempt organizations or spent

in the organization's own exempt activities during the tax year $

Part IV

Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

Return Reference	Explanation

Schedule G (Form 990) (Rev. 1-2025)

Additional Data

Software ID:
Software Version:

- TIN:

Note: To capture the full content of this document, please select landscape mode (11" x 8.5") when printing.

Schedule I
(Form 990)
(Rev. January 2025)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," on Form 990, Part IV, line 21 or 22.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public
Inspection

Name of the organization
ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number
52-2396428

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ........................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient

that received more than $5,000. Part II can be duplicated if additional space is needed.

(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(h) Purpose of grant or assistance
(1) AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC 1120 15TH STREET CJ3301 AUGUSTA,GA30912	58-1418202	501 (C)(3)	201,250	THE IMPACT OF SOLUBLE DIETARY FIBER ON TAU-MEDIATED NEURODEGENERATION IN A MOUSE MODEL OF TAUOPATHY
(2) BAYLOR COLLEGE OF MEDICINE 1 BAYLOR PLAZA HOUSTON,TX77030	74-1613878	501 (C)(3)	138,000	DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE
(3) BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON,MA02215	04-2103881	501 (C)(3)	201,250	INTEGRATING SINGLE-CELL GENOMICS FOR PATHWAYS TO PROTECTION AND RESILIENCE AGAINST ALZHEIMER'S DISEASE
(4) BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON,MA02215	04-2774441	501 (C)(3)	264,500	BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE (SUPPLEMENT)
(5) BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON,MA02215	04-2774441	501 (C)(3)	57,500	TRACKING INFLAMMATION AND REPAIR AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE
(6) BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON,MA02215	04-2774441	501 (C)(3)	344,528	NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE
(7) BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON,MA02215	04-2774441	501 (C)(3)	80,500	HOW BODY-BRAIN INFLAMMATORY SIGNALS VIA BORDER MACROPHAGES ALTER THE NEUROIMMUNE LANDSCAPE AND DRIVE ALZHEIMER'S PATHOLOGY
(8) BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON,MA02215	04-2312909	501 (C)(3)	575,000	APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS
(9) BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON,MA02215	04-2312909	501 (C)(3)	431,250	A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE
(10) BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON,MA02215	04-2312909	501 (C)(3)	201,250	VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN
(11) BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON,MA02215	04-2312909	501 (C)(3)	228,900	DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA?
(12) BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON,MA02215	04-2312909	501 (C)(3)	201,234	T CELL MODULATION OF MICROGLIA TO TREAT ALZHEIMER'S DISEASE
(13) BURKE NEUROLOGICAL INSTITUTE 785 MAMARONECK AVE WHITE PLAINS,NY106052523	13-3434924	501 (C)(3)	173,007	2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE
(14) CARNEGIE MELLON UNIVERSITY 5000 FORBES AVE PITTSBURGH,PA15213	25-0969449	501 (C)(3)	201,250	INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS
(15) COLUMBIA UNIVERSITY 630 WEST 168TH STREET BOX 49 NEW YORK,NY10032	13-5598093	501 (C)(3)	201,250	SEMAPHORIN REGULATION OF DISEASE-ASSOCIATED MICROGLIA IN ALZHEIMER'S DISEASE
(16) COLUMBIA UNIVERSITY 630 WEST 168TH STREET BOX 49 NEW YORK,NY10032	13-5598093	501 (C)(3)	201,250	NONCODING TRANSLATION FEEDBACK LOOP IN ALZHEIMER'S DISEASE
(17) DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL STREET SUITE 900 DURHAM,NC27701	56-2247203	501 (C)(3)	204,656	CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE
(18) DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL STREET SUITE 900 DURHAM,NC27701	56-2247203	501 (C)(3)	320,033	UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES
(19) EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR 1599-001-1BA ATLANTA,GA303224250	58-0566256	501 (C)(3)	201,250	MITOCHONDRIAL ALZHEIMER'S RISK FACTORS CONTROL APOE EXPRESSION AND SECRETION
(20) GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO,CA94158	23-7203666	501 (C)(3)	258,573	DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODELS (CFSF SUPPLEMENT)
(21) GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO,CA94158	23-7203666	501 (C)(3)	201,250	DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES
(22) GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO,CA94158	23-7203666	501 (C)(3)	258,615	DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES (CFSF SUPPLEMENT)
(23) GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO,CA94158	23-7203666	501 (C)(3)	201,250	DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODEL
(24) HOUSTON METHODIST RESEARCH INSTITUTE (HOUSTON METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON,TX77210	76-0094743	501 (C)(3)	201,167	A MUTI-MODALITY STUDY ON LIPID MOLECULAR BASIS OF OBESITY AND ITS ROLES IN REGULATING ALZHEIMER'S PATHOGENESIS FOR DEVELOPING POTENTIAL TARGETED INTERVENTIONS
(25) HOUSTON METHODIST RESEARCH INSTITUTE (HOUSTON METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON,TX77210	76-0094743	501 (C)(3)	57,500	CANCER-DERIVED EXTRACELLULAR VESICLE MICRORNAS AS SYSTEMIC MODULATORS OF ALZHEIMER'S DISEASE
(26) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK,NY10029	13-6171197	501 (C)(3)	201,235	RESTORING BRAIN COLLECTION IN NEW YORK CITY THROUGH THE MOUNT SINAI NEUROPATHOLOGY BRAIN BANK
(27) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK,NY10029	13-6171197	501 (C)(3)	150,786	ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER
(28) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK,NY10029	13-6171197	501 (C)(3)	230,000	INVESTIGATING THE PATHOGENETIC ROLE OF MICROGLIAL MEF2C IN ALZHEIMER'S DISEASE ACROSS THE LIFESPAN: DEVELOPMENTAL PRIMING VS. ADULT RESPONSE TO INJURY
(29) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK,NY10029	13-6171197	501 (C)(3)	80,500	COMBINATORIAL ROLES OF EED AND PICALM IN MICROGLIAL CLEARANCE PATHWAYS IN ALZHEIMER'S DISEASE
(30) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK,NY10029	13-6171197	501 (C)(3)	201,250	INVESTIGATING MEF2C TRANSCRIPTION FACTOR AS THERAPEUTIC TARGET TO REPROGRAM PATHOLOGICAL MICROGLIAL STATES IN ALZHEIMER'S DISEASE
(31) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK,NY10029	13-6171197	501 (C)(3)	201,250	INVESTIGATING THE ASSOCIATION BETWEEN CLONAL HEMATOPOIESIS AND ALZHEIMER'S DISEASE
(32) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK,NY10029	13-6171197	501 (C)(3)	115,000	CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION
(33) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK,NY10029	13-6171197	501 (C)(3)	201,250	ROLE OF PSYCHOSOCIAL STRESS IN ALZHEIMER'S DISEASE
(34) JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE,MD21205	52-0595110	501 (C)(3)	201,250	A TEMPORALLY ALIGNED MULTIMODAL FRAMEWORK FOR INDIVIDUALIZED ALZHEIMER'S DISEASE RISK ASSESSMENT AND DEEP LEARNING-DRIVEN PROGNOSIS
(35) JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE,MD21205	52-0595110	501 (C)(3)	143,697	BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY
(36) JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE,MD21205	52-0595110	501 (C)(3)	201,250	FROM MOLECULAR HETEROGENEITY TO PREDICTIVE MEDICINE: TRANSFORMING NEURODEGENERATIVE DISEASE RESEARCH THROUGH SPATIAL MULTI-OMICS AND INTERPRETABLE AI
(37) MARYLAND MEDICAL LEGAL FOUNDATION 900 WEST BALTIMORE STREET BALTIMORE,MD21223	52-0786068	501 (C)(3)	57,500	BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY
(38) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	287,500	BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE
(39) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	4,025	ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS (SUPPLEMENT)
(40) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	201,250	RIN3 AND BIN1 INTERACTION CONNECTS ENDOSOMAL PATHOLOGY WITH AMYLOID PATHOLOGY
(41) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	201,250	TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN
(42) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	201,250	PRECISION GENE THERAPY TARGETING MICROGLIA IN ALZHEIMER'S DISEASE
(43) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	201,250	ENGINEERING A HUMAN REGION-SPECIFIC SYSTEM TO PROBE APOE-LINKED CELLULAR VULNERABILITY AND RESILIENCE IN ALZHEIMER'S DISEASE
(44) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	100,625	AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE
(45) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	258,750	EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS (CFSF SUPPLEMENT)
(46) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	201,250	EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS
(47) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	201,250	CENTENARIAN MICROGLIA REVEAL A NEPRILYSIN-DEPENDENT MECHANISM OF RESILIENCE IN ALZHEIMER'S DISEASE
(48) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	230,000	ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE
(49) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	1,955,000	THE CUREALZ ALZHEIMER'S GENOME PROJECT
(50) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	100,600	ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS
(51) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON,MA02114	04-1564655	501 (C)(3)	100,625	CHARACTERIZATION AND OPTIMIZATION OF CNS-PENETRANT HDAC11-SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS
(52) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-2697983	501 (C)(3)	258,750	ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (CFSF SUPPLEMENT)
(53) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-2697983	501 (C)(3)	252,076	MENOPAUSE AND RELATED MIDLIFE RISK FACTORS AND THEIR IMPACT ON PATHOLOGY AND COGNITION - THE WHIMSYAD STUDY
(54) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-2697983	501 (C)(3)	201,250	IDENTIFYING SEX-AWARE X-CHROMOSOME TARGETS FOR PRECLINICAL ALZHEIMER'S DISEASE
(55) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-2697983	501 (C)(3)	300,000	UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY
(56) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-2697983	501 (C)(3)	8,533	ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (SUPPLEMENT)
(57) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-2697983	501 (C)(3)	201,250	CIRCUIT DYNAMICS IN APOE4 MICE
(58) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-2697983	501 (C)(3)	201,250	INTERNEURON THERAPY FOR ALZHEIMER'S DISEASE
(59) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-2697983	501 (C)(3)	201,250	DEVELOPMENT OF A FLAP-TARGETED NEUROIMMUNE PET TRACER FOR IMAGING MICROGLIA IN AD
(60) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02114	04-2697983	501 (C)(3)	200,416	CIRCADIAN PERTURBATIONS OF THE VASCULOME AND MICROGLIOME IN ALZHEIMER'S DISEASE
(61) MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE,MA02139	04-2103594	501 (C)(3)	287,477	BAC: INVESTIGATING LIPIDOMIC PERTURBATIONS IN THE CSF WITH AGE AND ALZHEIMER'S DISEASE PROGRESSION: TOWARD MECHANISTIC INSIGHTS AND ACCESSIBLE LIPID BIOMARKERS
(62) MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE,MA02139	04-2103594	501 (C)(3)	9,752	DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE (SUPPLEMENT)
(63) MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE,FL322241865	59-3337028	501 (C)(3)	201,250	LINKING SLEEP DYSFUNCTION TO TAU-RELATED DEGENERATION ACROSS AD VARIANTS
(64) MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE,FL322241865	59-3337028	501 (C)(3)	201,250	THE MULTI-OMIC ROADMAP TO NEURONAL SENESCENCE IN ALZHEIMER'S DISEASE
(65) MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE,FL322241865	59-3337028	501 (C)(3)	230,000	UNRAVELING MIXED PATHOLOGY AND ITS IMPACT ON THE PROTEOME IN ALZHEIMER'S DISEASE
(66) MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE,FL322241865	59-3337028	501 (C)(3)	201,250	EVALUATING THE CONTRIBUTION OF TDP-43 DYSFUNCTION AND CRYPTIC MIS-SPLICING TO AD PATHOGENESIS
(67) MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE,FL322241865	59-3337028	501 (C)(3)	201,250	ELUCIDATING THE PROTECTIVE EFFECTS OF APOE2 IN THE PRESENCE OF APOE 4 GENE ALLELE IN ANIMAL MODELS
(68) MAYO CLINIC ROCHESTER 200 FIRST ST SW ROCHESTER,MN55905	41-6011702	501 (C)(3)	201,250	BRIDGING THE GAP: SEX-SPECIFIC DRIVERS OF SENESCENCE UNDERLYING NEURODEGENERATION
(69) MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK,NY10065	13-1924236	501 (C)(3)	201,250	DEVELOPMENT AND MECHANISM OF AUTOPHAGY ACTIVATORS FOR TREATMENT OF ALZHEIMER'S DISEASE
(70) NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE 900 ROCKVILLE PIKE BETHESDA,MD20892	52-0858115	GOVERNMENT	287,673	BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS
(71) NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE 900 ROCKVILLE PIKE BETHESDA,MD20892	52-0858115	GOVERNMENT	80,500	DYNAMIC INVESTIGATION OF LYMPHATIC PATHWAY INTERCONNECTIONS FOR CEREBROSPINAL FLUID CLEARANCE OF THE HUMAN CENTRAL NERVOUS SYSTEM IN VIVO UNDER PHYSIOLOGICAL CONDITIONS OF THE BRAIN'S BORDERS
(72) SEATTLE NEUROSOUND SOLUTIONS 1126 38TH AVENUE EAST SEATTLE,WA98112	88-4199640		175,000	CONTINUOUS MONITORING AND ENHANCEMENT OF GLYMPHATIC FLOW IN HUMAN SLEEP
(73) NEW YORK GENOME CENTER 101 AVENUE OF THE AMERICAS 7TH FLOOR NEW YORK,NY10013	80-0631734	501 (C)(3)	86,250	CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION
(74) NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK,NY10016	13-5562308	501 (C)(3)	201,250	MIDLIFE AUTOANTIBODY PROFILES AND THE RISK OF LATE-ONSET ALZHEIMER'S DISEASE IN WOMEN
(75) NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK,NY10016	13-5562308	501 (C)(3)	210,962	MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE
(76) NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK,NY10016	13-5562308	501 (C)(3)	287,500	NIC: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO AD
(77) NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK,NY10016	13-5562308	501 (C)(3)	80,500	ASTROCYTE NETWORK STRUCTURE AND FUNCTION IN ALZHEIMER'S DISEASE
(78) NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK,NY10016	13-5562308	501 (C)(3)	201,250	VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN
(79) NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE ABBOTT 1416 CHICAGO,IL60611	36-2167817	501 (C)(3)	201,250	SEX-SPECIFIC MECHANISMS OF NEUROINFLAMMATION IN THE ALZHEIMER'S DISEASE HYPOTHALAMUS
(80) NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE ABBOTT 1416 CHICAGO,IL60611	36-2167817	501 (C)(3)	201,250	ROLE OF TAU IN PRESYNAPTIC DYSFUNCTION DURING THE CELLULAR PHASE OF ALZHEIMER'S DISEASE
(81) NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE ABBOTT 1416 CHICAGO,IL60611	36-2167817	501 (C)(3)	57,500	ROLE OF ANNEXIN A6-MEDIATED MEMBRANE REPAIR IN ALZHEIMER'S PATHOLOGY
(82) PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE,MA02138	04-2103580	501 (C)(3)	38,944	PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA (SUPPLEMENT)
(83) PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE,MA02138	04-2103580	501 (C)(3)	230,000	MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY
(84) PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE,MA02138	04-2103580	501 (C)(3)	80,500	FBAT-EQUIVALENCE TESTING IN THE PRESENCE OF MODEL UNCERTAINTY FOR THE CURE ALZHEIMERS GENOME PROJECT
(85) PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE,MA02138	04-2103580	501 (C)(3)	201,250	MENINGEAL TREGS IN INDIVIDUALS WITH VS WITHOUT ALZHEIMER'S DISEASE
(86) REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA,CA920930636	95-2872494	501 (C)(3)	201,250	DYSREGULATION OF SIGNALING ON POST SYNAPTIC DENSITY SCAFFOLDS IN ALZHEIMER'S DISEASE
(87) REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA,CA920930636	95-2872494	501 (C)(3)	150,937	THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION
(88) REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA,CA920930636	95-2872494	501 (C)(3)	201,250	SON-DEPENDENT NUCLEAR SPECKLE REJUVENATION: A NOVEL PROTEOSTASIS-BASED THERAPEUTIC STRATEGY FOR ALZHEIMER'S DISEASE
(89) REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA,CA920930636	95-2872494	501 (C)(3)	287,500	BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE?
(90) REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA,CA920930636	95-2872494	501 (C)(3)	80,500	MECHANISMS REGULATING NEUROVASCULAR FUNCTION IN ALZHEIMER'S DISEASE
(91) REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA,CA920930636	95-2872494	501 (C)(3)	287,500	NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION
(92) REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA,CA920930636	95-2872494	501 (C)(3)	230,000	APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER DISEASE IN DOWN SYNDROME
(93) ST JUDE CHILDREN'S RESEARCH HOSPITAL 262 DANNY THOMAS PLACE MEMPHIS,TN38105	62-0646012	501 (C)(3)	92,000	DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE
(94) STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY,CA94063	94-1156365	501 (C)(3)	198,253	BMP LIPID METABOLISM AS A THERAPEUTIC TARGET FOR LYSOSOMAL FUNCTION AND ALZHEIMER'S DISEASE PATHOGENESIS
(95) STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY,CA94063	94-1156365	501 (C)(3)	198,370	OLIGODENDROGLIAL DYNAMICS AND MYELINATION IN ALZHEIMER'S DISEASE
(96) STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY,CA94063	94-1156365	501 (C)(3)	287,500	BAC: CHOROID PLEXUS AGING AND ALZHEIMER'S DISEASE
(97) STATE OF MARYLAND -UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE,MD212036428	52-6002033	501 (C)(3)	171,037	EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS
(98) THE BROAD INSTITUTE INC 415 MAIN STREET CAMBRIDGE,MA02142	26-3428781	501 (C)(3)	230,000	INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS
(99) THE MCLEAN HOSPITAL CORPORATION 115 MILL STREET BELMONT,MA02478	04-2697981	501 (C)(3)	327,501	EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS
(100) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO,CA94143	94-3067788	501 (C)(3)	201,250	NEURONAL MECHANISMS DRIVING SYNAPSE LOSS IN ALZHEIMER'S DISEASE
(101) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO,CA94143	94-3067788	501 (C)(3)	201,250	PROBING THE MOLECULAR UNDERPINNINGS OF HOW G PROTEIN-COUPLED RECEPTOR ADGRG1 MEDIATES PROTECTIVE RESPONSES TO ALZHEIMER'S DISEASE
(102) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO,CA94143	94-3067788	501 (C)(3)	80,500	DEFINE ADGRG1-MEDIATED PROTECTIVE MICROGLIAL RESPONSE TO TAU TANGLES IN ALZHEIMER'S DISEASE
(103) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO,CA94143	94-3067788	501 (C)(3)	201,250	ROLE OF PLATELET-DERIVED FACTORS IN AMELIORATING ALZHEIMER'S DISEASE PATHOLOGY
(104) THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 NORTH TORREY PINES ROAD LA JOLLA,CA92037	95-2160097	501 (C)(3)	201,250	THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE
(105) TRUSTEES OF TUFTS COLLEGE DBA TUFTS UNIVERSITY 80 GEORGE ST MEDFORD,MA02155	04-2103634	501 (C)(3)	100,625	ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS
(106) UNIVERSITY OF ALABAMA AT BIRMINGHAM 801 5TH AVE SOUTH ROOM 251 BIRMINGHAM,AL35233	63-6005396	501 (C)(3)	271,375	EXPANDING DEEP SOUTH INCLUSION IN THE UAB ADRC NEUROPATHOLOGY CORE BRAIN BANK
(107) UNIVERSITY OF CALIFORNIA DAVIS ONE SHIELDS AVENUE DAVIS,CA95616	94-3067788	501 (C)(3)	201,250	DECIPHERING PHOSPHORYLATION-DEPENDENT TAU ENVELOPE DYSFUNCTION TO PREVENT ALZHEIMER'S NEURODEGENERATION
(108) UNIVERSITY OF CALIFORNIA DAVIS ONE SHIELDS AVENUE DAVIS,CA95616	94-3067788	501 (C)(3)	286,466	NIC: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION
(109) UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE,CA92697	95-2226406	501 (C)(3)	287,490	NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS
(110) UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE,CA92697	95-2226406	501 (C)(3)	230,000	ENGINEERED CAR-MACROPHAGES TO CLEAR TAU
(111) UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE,CA92697	95-2226406	501 (C)(3)	402,492	PROTEOMIC SIGNATURES OF CEREBROVASCULAR NEUROPATHOLOGY IN DOWN SYNDROME WITH ALZHEIMER DISEASE
(112) UNIVERSITY OF CALIFORNIA LOS ANGELES 10920 WILSHIRE BOULEVARD SUITE 600 LOS ANGELES,CA90024	95-6006143	501 (C)(3)	191,463	NOVEL AI DECODES AGING NEURONS
(113) UNIVERSITY OF KENTUCKY 109 KINKEAD HALL LEXINGTON,KY405060057	61-6033693	501 (C)(3)	78,090	ASSESSING THE ROLE OF APOE IN GLIAL LIPID DROPLET METABOLISM AND FUNCTION
(114) UNIVERSITY OF KENTUCKY 109 KINKEAD HALL LEXINGTON,KY405060057	61-6033693	501 (C)(3)	200,187	LOWERING MICROGLIAL LIPID BURDEN VIA PLIN2 MODULATION IN ALZHEIMER'S DISEASE
(115) UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER,MA01655	04-3167352	501 (C)(3)	200,568	VENTRICULAR EPENDYMAL CELLS: A NOVEL NEURAL-IMMUNE SIGNALING AXIS DURING AGING AND NEURODEGENERATION
(116) UNIVERSITY OF MIAMI PO BOX 405803 ATLANTA,GA30384	59-0624458	501 (C)(3)	24,589	2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE
(117) UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR,MI481091287	38-6006309	501 (C)(3)	398,521	UTILIZING HETEROGENEOUS MOUSE MODELS TO DISCOVER MECHANISMS UNDERLYING CALORIC RESTRICTION (CR) ON COGNITIVE OUTCOMES
(118) UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR,MI481091287	38-6006309	501 (C)(3)	201,251	MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD
(119) UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR,MI481091287	38-6006309	501 (C)(3)	402,500	NON-INVASIVE MODULATION OF MICROGLIA GENE EXPRESSION USING PERIPHERALLY ADMINISTERED ANTIBODY CONJUGATES
(120) UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR,MI481091287	38-6006309	501 (C)(3)	103,168	NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY
(121) UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET 5TH FLOOR FRANKLIN BUILDING PHILADELPHIA,PA191046205	23-1352685	501 (C)(3)	284,678	APOE CONSORTIUM: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY
(122) UNIVERSITY OF PITTSBURGH 200 S CRAIG ST SUITE 230 PITTSBURGH,PA15260	25-0965591	501 (C)(3)	100,625	AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE
(123) UNIVERSITY OF ROCHESTER 910 GENESEE STREET SUITE 200 ROCHESTER,NY146113847	16-0743209	501 (C)(3)	287,500	BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE?
(124) UNIVERSITY OF SOUTH FLORIDA 4202 E FOWLER AVE SVC 1039 TAMPA,FL336205800	59-3102112	501 (C)(3)	201,250	BIN1 IN MICROGLIAL HETEROGENEITY ALONG AD PROGRESSION AND MICROGLIAL FUNCTION
(125) UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA STREET SUITE 102 LOS ANGELES,CA900898001	95-1642394	501 (C)(3)	57,500	NEURAL STEM CELL REJUVENATION FOR SYMPTOMATIC ALZHEIMER'S DISEASE
(126) UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE MSC 7828 SAN ANTONIO,TX78229	74-1586031	501 (C)(3)	181,004	BRIDGING MYELIN AND VASCULAR DEMENTIA: OLIGODENDROCYTE STRESS RESPONSES IN AGEING AND CEREBROVASCULAR DISEASE
(127) UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE MSC 7828 SAN ANTONIO,TX78229	74-1586031	501 (C)(3)	201,250	HOW DO MICROGLIA CONTRIBUTE TO THE SPREAD OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE?
(128) UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE MSC 7828 SAN ANTONIO,TX78229	74-1586031	501 (C)(3)	201,250	DIGITAL NEUROPATHOLOGY INFRASTRUCTURE FOR PRECISION MEDICINE IN SOUTH TEXAS HISPANIC AD/ADRD POPULATIONS
(129) UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE MSC 7828 SAN ANTONIO,TX78229	74-1586031	501 (C)(3)	201,250	COGNITIVELY HEALTHY NONAGENARIANS IN THE CROSS COHORT COLLABORATION (CCC)
(130) UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS,TX75390	75-6002868	501 (C)(3)	230,000	ENGINEERED CAR-MACROPHAGES TO CLEAR TAU
(131) UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE,VA229044195	54-6001796	501 (C)(3)	201,250	MICROGLIAL MITOCHONDRIAL DYSFUNCTION AND TAU TOXICITY IN ALZHEIMER'S DISEASE
(132) UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE,VA229044195	54-6001796	501 (C)(3)	201,250	IMPACT OF DNA DAMAGE-MEDIATED STING ACTIVATION ON MYELIN FUNCTION IN AN ALZHEIMER'S DISEASE ANIMAL MODEL
(133) UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE,VA229044195	54-6001796	501 (C)(3)	258,750	THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION (CFSF SUPPLEMENT)
(134) UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE,VA229044195	54-6001796	501 (C)(3)	201,250	ELUCIDATING THE ROLE OF EMERGING GENOMIC STRESS SENSORS IN AD
(135) UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE,VA229044195	54-6001796	501 (C)(3)	50,312	THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION
(136) UNIVERSITY OF WASHINGTON 4300 ROOSEVELT WAY NE BOX 354965 SEATTLE,WA98105	91-6001537	501 (C)(3)	200,043	ELUCIDATING THE THERAPEUTIC POTENTIAL OF THE ENDO-LYSOSOME PATHWAY FOR ALZHEIMER'S DISEASE
(137) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	201,250	SLEEP REINFORCES HOMEOSTATIC SET-POINTS IN NEURAL ACTIVITY AND MITIGATES NEURODEGENERATIVE DISEASE
(138) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	345,000	APOE CONSORTIUM: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS
(139) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	345,000	BAC: IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN ALZHEIMER'S DISEASE
(140) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	182,921	MAPPING THE X CHROMOSOME MULTI-OME IN ALZHEIMER'S AND PARKINSON'S DISEASE
(141) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	201,250	DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF CHOLESTEROL 25-HYDROXYLASE
(142) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	200,530	MULTIOMIC AND FUNCTIONAL CHARACTERIZATION OF STREM2 MODIFIERS
(143) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	201,250	TARGETING REACTIVE ASTROCYTES AMPK SIGNALING TO SUPPRESS INFLAMMATION IN ALZHEIMER'S DISEASE
(144) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	77,709	SUPPRESSING NEUROINFLAMMATION WITH A TARGETED PROTEIN DEGRADATION STRATEGY IN A TAUOPATHY MOUSE MODEL
(145) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	201,250	DECIPHERING AND RESTORING COMPUTATIONAL SET-POINTS IN ALZHEIMER'S DISEASE THROUGH SLEEP-ENHANCED NETWORK HOMEOSTASIS
(146) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	80,500	SLEEP AUGMENTATION REINFORCES NEURAL COMPUTATION, ENHANCES COGNITION, AND MITIGATES NEURODEGENERATIVE DISEASE SYMPTOMS
(147) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	201,250	ANTIVIRAL CYTOKINE SIGNALING PROMOTES NEURODEGENERATION IN ALZHEIMER'S DISEASE
(148) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	345,000	BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE
(149) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	201,212	NEUROPROTECTIVE T CELL-BASED THERAPY FOR ALZHEIMER'S DISEASE
(150) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	124,653	CHARACTERIZATION OF ALZHEIMER'S DISEASE MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM
(151) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	199,281	CIRCADIAN DESYNCHRONY, GLIAL DYSFUNCTION, AND ALZHEIMER DISEASE PATHOGENESIS
(152) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	287,500	BAC: BRAIN REGION AND CELL-TYPE SPECIFIC AGING FROM ACCELERATED TO RESILIENT TRAJECTORIES
(153) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	201,250	SPECIFICITY OF T CELL RESPONSES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD)
(154) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	98,083	NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY
(155) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	287,499	BAC: ESTABLISHING ISOGENIC MODELS OF HUMAN NEURON AGING AND PATHWAYS RELEVANT FOR ALZHEIMER'S DISEASE
(156) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS,MO63130	43-0653611	501 (C)(3)	201,250	THE JEFFREY L. MORBY PRIZE
(157) WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK,NY100654805	13-6094042	501 (C)(3)	80,500	MICROGLIAL-ASTROCYTIC MECHANISMS OF APOE3 CHRISTCHURCH-MEDIATED RESILIENCE TO TAUOPATHY
(158) WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK,NY100654805	13-6094042	501 (C)(3)	402,500	SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES
(159) WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK,NY100654805	13-6094042	501 (C)(3)	200,532	HYPERTENSION, TAU AND NEURODEGENERATION
(160) WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK,NY100654805	13-6094042	501 (C)(3)	201,250	A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION
(161) WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK,NY100654805	13-6094042	501 (C)(3)	258,750	A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION (CFSF SUPPLEMENT)

Enter total number of section 501(c)(3) and government organizations listed in the line 1 table .................

Enter total number of other organizations listed in the line 1 table ........................ .

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) Rev. 1-2025

Page 2

Part III

Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of noncash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

(1)
(2)
(3)
(4)
(5)
(6)
(7)

Part IV

Supplemental Information. Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

Return Reference

Explanation

PART I, LINE 2:

THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED.

Schedule I (Form 990) Rev. 1-2025

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)
(Rev. January 2025)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization

ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number

52-2396428

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed on Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes on Line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain .....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked on Line 1a? ....

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? .............

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ....................

Any related organization? .......................

If "Yes," on line 5a or 5b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ..................

Any related organization? ......................

If "Yes," on line 6a or 6b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Were any amounts reported on Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III ..........................

If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) (Rev. 1-2025)

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2, 1099-MISC compensation, and/or 1099-NEC			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
1MARGARET E SMITH CEO & DIRECTOR	(i) (ii)	436,310 ------------- 0	65,250 ------------- 0	0 ------------- 0	10,500 ------------- 0	19,119 ------------- 0	531,179 ------------- 0	0 ------------- 0
2KATHARINE HERMAN EVP DEVELOPMENT	(i) (ii)	372,022 ------------- 0	86,500 ------------- 0	0 ------------- 0	10,500 ------------- 0	20,535 ------------- 0	489,557 ------------- 0	0 ------------- 0
3BARBARA CHAMBERS EVP MARKETING & COMM.	(i) (ii)	283,531 ------------- 0	19,500 ------------- 0	0 ------------- 0	9,511 ------------- 0	14,967 ------------- 0	327,509 ------------- 0	0 ------------- 0
4LISA RAND VP MARKETING & COMM.	(i) (ii)	208,091 ------------- 0	9,000 ------------- 0	0 ------------- 0	6,821 ------------- 0	12,673 ------------- 0	236,585 ------------- 0	0 ------------- 0
5DANIEL HARPER VP DEVELOPMENT	(i) (ii)	206,418 ------------- 0	14,500 ------------- 0	0 ------------- 0	6,731 ------------- 0	7,630 ------------- 0	235,279 ------------- 0	0 ------------- 0
6JOSEPHINE ANTONELLIS CFO	(i) (ii)	204,692 ------------- 0	20,500 ------------- 0	0 ------------- 0	6,763 ------------- 0	1,239 ------------- 0	233,194 ------------- 0	0 ------------- 0
7JOHN SLATTERY SVP, PHILANTHROPIC PARTNERSHIPS	(i) (ii)	204,048 ------------- 0	9,500 ------------- 0	0 ------------- 0	6,502 ------------- 0	960 ------------- 0	221,010 ------------- 0	0 ------------- 0
8MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR	(i) (ii)	181,723 ------------- 0	12,000 ------------- 0	0 ------------- 0	6,237 ------------- 0	20,517 ------------- 0	220,477 ------------- 0	0 ------------- 0
9THIDAPHORN SENGSAVANH DIRECTOR OF DEVELOPMENT OPERATIONS	(i) (ii)	163,396 ------------- 0	7,500 ------------- 0	0 ------------- 0	5,403 ------------- 0	20,279 ------------- 0	196,578 ------------- 0	0 ------------- 0

Schedule J (Form 990) (Rev. 1-2025)

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Return Reference	Explanation

Schedule J (Form 990) (Rev. 1-2025)

Additional Data

Software ID:
Software Version:

- TIN:

Schedule L
(Form 990)
(Rev. January 2025)

Department of the Treasury
Internal Revenue Service

Transactions with Interested Persons

Complete if the organization answered "Yes" on Form 990, Part IV, lines 25a, 25b, 26, 27, 28a, 28b, or 28c, or Form 990-EZ, Part V, line 38a or 40b.
Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization

ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number

52-2396428

Part I

Excess Benefit Transactions (section 501(c)(3), section 501(c)(4), and section 501(c)(29) organizations only).
Complete if the organization answered "Yes" on Form 990, Part IV, line 25a or 25b, or Form 990-EZ, Part V, line 40b.

1(a) Name of disqualified person	(c) Description of transaction	(d) Corrected?
1(a) Name of disqualified person	(c) Description of transaction	Yes	No

Enter the amount of tax incurred by the organization managers or disqualified persons during the year under section 4958. ........................... $

Enter the amount of tax, if any, on line 2, above, reimbursed by the organization ........ $

Part II

Loans to and/or From Interested Persons.
Complete if the organization answered "Yes" on Form 990-EZ, Part V, line 38a, or Form 990, Part IV, line 26; or if the organization reported an amount on Form 990, Part X, line 5, 6, or 22

(a) Name of interested person	(b) Relationship with organization	(c) Purpose of loan	(d) Loan to or from the organization?		(e) Original principal amount	(f) Balance due	(g) In default?		(h) Approved by board or committee?		(i) Written agreement?
(a) Name of interested person	(b) Relationship with organization	(c) Purpose of loan	To	From	(e) Original principal amount	(f) Balance due	Yes	No	Yes	No	Yes	No




Total ............... $

Part III

Grants or Assistance Benefiting Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 27.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of assistance	(d) Type of assistance	(e) Purpose of assistance

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 50056A

Schedule L (Form 990) (Rev. 1-2025)

Page 2

Part IV

Business Transactions Involving Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 28a, 28b, or 28c.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of transaction	(d) Description of transaction	(e) Sharing of organization's revenues?
(a) Name of interested person		(c) Amount of transaction	(d) Description of transaction	Yes	No
(1) PROPER VILLAINS LLC	A PRINCIPAL OF THE INDEPENDENT CONTRACTOR IS THE SPOUSE OF A KEY EMPLOYEE	130,663	CREATIVE AND PRODUCTION SERVICES		No

Part V

Supplemental Information
Provide additional information for responses to questions on Schedule L (see instructions).

Return Reference	Explanation

Schedule L (Form 990) (Rev. 1-2025)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Attach to Form 990.
Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2025

Open to Public Inspection

Name of the organization

ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number

52-2396428

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	92	5,646,939	FMV
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( AUCTION ITEMS )	X	10	28,302	FMV
26 Other ( )
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? ...................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

Yes

If "Yes," describe in Part II.

If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2025)

Page 2

Part IISupplemental Information. Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Return Reference	Explanation
PART I, LINE 32B:	WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH JP MORGAN AND BANK OF NEW YORK/MELLON.

Schedule M (Form 990) (2025)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990)
(Rev. January 2025)
Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public
Inspection

Name of the organization

ALZHEIMER'S DISEASE RESEARCH FOUNDATION

Employer identification number

52-2396428

Return Reference	Explanation
FORM 990, PART VI, SECTION B, LINE 11B	THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS.
FORM 990, PART VI, SECTION B, LINE 12C	EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION.
FORM 990, PART VI, SECTION B, LINE 15	COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE CEO AND ALL OTHER EMPLOYEES.
FORM 990, PART VI, SECTION C, LINE 19	THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE.
FORM 990, PART XII, LINE 2C	THE ORGANIZATION DID NOT CHANGE EITHER ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990) (Rev. 1-2025)

Additional Data

Software ID:
Software Version:

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	30,788,755	55,333,840
9	Program service revenue (Part VIII, line 2g) .........	0	0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	964,653	1,312,647
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	2,269	13,348
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	31,755,677	56,659,835
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	28,828,950	37,323,497
14	Benefits paid to or for members (Part IX, column (A), line 4).....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	5,244,116	5,904,594
16a	Professional fundraising fees (Part IX, column (A), line 11e) .....	0	0
b	Total fundraising expenses (Part IX, column (D), line 25) 2,357,449
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	2,926,002	3,004,585
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	36,999,068	46,232,676
19	Revenue less expenses. Subtract line 18 from line 12.......	-5,243,391	10,427,159
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	28,586,231	43,169,584
21	Total liabilities (Part X, line 26).............	1,722,043	6,057,359
22	Net assets or fund balances. Subtract line 21 from line 20.....	26,864,188	37,112,225

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 38,338,893 including grants of $ 37,323,497 ) (Revenue $ )
	IN 2025, CURE ALZHEIMER'S FUND SUPPORTED 161 RESEARCH PROJECTS AT 74 LEADING RESEARCH INSTITUTIONS, FOR A TOTAL RESEARCH OUTPUT OF $38.3 MILLION. PROJECTS IDENTIFIED AND INVESTIGATED MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE AS POTENTIAL THERAPEUTIC TARGETS. OTHER STANDALONE PROJECTS AND MULTI-LAB CONSORTIA PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLE OF NEUROINFLAMMATION, THE GUT MICROBIOME, AND THE IMMUNE SYSTEM IN HEALTHY BRAIN FUNCTION. CUREALZ ALSO PROVIDED FUNDING TO SUSTAIN VITAL RESEARCH ASSETS, LIKE BRAIN BANKS AND SCIENTIFIC TRAINEES, FACING UNANTICIPATED REDUCTIONS IN FEDERAL SUPPORT. ADDITIONAL EXPENSES INCLUDE SCIENTIFIC MEETING HOSTING; HUSBANDRY OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH ASSESSING RESEARCH PROPOSALS AND DETERMINING FUNDING PRIORITIES.

4b	(Code: ) (Expenses $ 4,220,285 including grants of $ ) (Revenue $ )
	CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, WEBINARS, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED FOR MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE.

4c	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )












4d	Other program services (Describe in Schedule O.)
	(Expenses $ including grants of $ ) (Revenue $ )
4e	Total program service expenses42,559,178

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)		(D) Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
(A) Name and title
(18) JOHN SLATTERY........................................................................ SVP, PHILANTHROPIC PARTNERSHIPS	40.00 .......................	X	213,548	0	7,462
(19) MAHUA DASGUPTA........................................................................ SR. PHILANTROPIC ADVISOR	40.00 .......................	X	193,723	0	26,754
(20) THIDAPHORN SENGSAVANH........................................................................ DIRECTOR OF DEVELOPMENT OPERATIONS	40.00 .......................	X	170,896	0	25,682

1b	Sub-Total..............
c	Total from continuation sheets to Part VII, Section A..
d	Total (add lines 1b and 1c).........	2,638,167	0	191,542

1	Briefly describe the organization’s mission or most significant activities: TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	11
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	10
5	Total number of individuals employed in calendar year 2025 (Part V, line 2a) ......	5	38
6	Total number of volunteers (estimate if necessary) .............	6	100
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	0
b	Net unrelated business taxable income from Form 990-T, Part I, line 11 .........	7b	0

(A) Name and business address	(B) Description of services	(C) Compensation
PROPER VILLAINS LLC 855 BOYLSTON STREET 10TH FLOOR BOSTON,MA02116	CREATIVE AND PRODUCTION SERVICES	130,663




2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 1

1a	Federated campaigns..		1a
b	Membership dues..		1b
c	Fundraising events..		1c	321,940
d	Related organizations		1d
e	Government grants (contributions)		1e

f	All other contributions, gifts, grants, and similar amounts not included above		1f	55,011,900

g	Noncash contributions included in lines 1a - 1f:$		1g	5,675,241

h Total. Add lines 1a-1f.......		55,333,840

		Business Code
2a
b
c
d
e
f	All other program service revenue.
g	Total. Add lines 2a–2f .....

3 Investment income (including dividends, interest, and othersimilar amounts) ......			1,334,483			1,334,483
4 Income from investment of tax-exempt bond proceeds
5 Royalties...........
			(i) Real	(ii) Personal
6a	Gross rents	6a
b	Less: rental expenses	6b
c	Rental income or (loss)	6c
d	Net rental income or (loss).......
			(i) Securities	(ii) Other
7a	Gross amount from sales of assets other than inventory	7a	5,687,546
b	Less: cost or other basis and sales expenses	7b	5,709,382
c	Gain or (loss)	7c	-21,836
d	Net gain or (loss).........			-21,836			-21,836
8a	Gross income from fundraising events (not including $ 321,940of contributions reported on line 1c). See Part IV, line 18 ....
			8a	108,700
b	Less: direct expenses ...		8b	95,352
c	Net income or (loss) from fundraising events..			13,348			13,348
9a	Gross income from gaming activities. See Part IV, line 19 ...
			9a
b	Less: direct expenses ...		9b
c	Net income or (loss) from gaming activities..
10a	Gross sales of inventory, less returns and allowances ..
			10a
b	Less: cost of goods sold ..		10b
c	Net income or (loss) from sales of inventory..

Business Code
11a
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......
12	Total revenue. See instructions.....			56,659,835	0	0	1,325,995

1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21 ....	33,812,354	33,812,354
2	Grants and other assistance to domestic individuals. See Part IV, line 22 ...........
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16. .............	3,511,143	3,511,143
4	Benefits paid to or for members .......
5	Compensation of current officers, directors, trustees, and key employees ...........	1,719,780	929,771	412,287	377,722
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) .........
7	Other salaries and wages........	3,414,234	1,994,996	454,082	965,156
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	80,940	50,437	8,766	21,737
9	Other employee benefits .......	336,158	193,636	55,697	86,825
10	Payroll taxes ...........	353,482	199,198	60,093	94,191
11	Fees for services (non-employees):
a	Management ......
b	Legal .........	105,987	963	18,560	86,464
c	Accounting ...........	40,676		40,676
d	Lobbying ...........
e	Professional fundraising services. See Part IV, line 17
f	Investment management fees ......	53,906		53,906
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)	597,442	322,780	48,011	226,651
12	Advertising and promotion ....	811,566	811,566
13	Office expenses .......	180,267	108,285	26,885	45,097
14	Information technology ......	176,806	77,747	72,554	26,505
15	Royalties ..
16	Occupancy ...........	96,980	56,117	15,933	24,930
17	Travel ............	133,968	56,599	1,110	76,259
18	Payments of travel or entertainment expenses for any federal, state, or local public officials .
19	Conferences, conventions, and meetings ....	349,673	299,741	18,702	31,230
20	Interest ...........
21	Payments to affiliates .......
22	Depreciation, depletion, and amortization ..	2,896	744	476	1,676
23	Insurance ...	28,809	5,267	21,202	2,340
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	GIFT PROCESSING FEES	266,060			266,060
b	RESEARCH LAB EXPENSES	86,974	86,974
c	MISCELLANEOUS	72,575	40,860	7,109	24,606
d
e	All other expenses
25	Total functional expenses. Add lines 1 through 24e	46,232,676	42,559,178	1,316,049	2,357,449
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).

1	Cash–non-interest-bearing ........			2,815,537	1	3,565,286
2	Savings and temporary cash investments .........			322,954	2	1,802,130
3	Pledges and grants receivable, net ......			1,707,733	3	9,622,053
4	Accounts receivable, net .............				4
5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .......
					5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) ...
					6
7	Notes and loans receivable, net ...........				7
8	Inventories for sale or use ............				8
9	Prepaid expenses and deferred charges ......			246,040	9	321,471
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	8,688
b	Less: accumulated depreciation	10b	3,620	7,964	10c	5,068
11	Investments—publicly traded securities .			23,255,145	11	27,704,096
12	Investments—other securities. See Part IV, line 11 .....				12
13	Investments—program-related. See Part IV, line 11 ..				13
14	Intangible assets ...............				14
15	Other assets. See Part IV, line 11 ...........			230,858	15	149,480
16	Total assets. Add lines 1 through 15 (must equal line 33)...			28,586,231	16	43,169,584

17	Accounts payable and accrued expenses .....	167,083	17	363,629
18	Grants payable ...	600,901	18	4,812,010
19	Deferred revenue .........		19
20	Tax-exempt bond liabilities .........		20
21	Escrow or custodial account liability. Complete Part IV of Schedule D		21
22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .........
			22
23	Secured mortgages and notes payable to unrelated third parties ..		23
24	Unsecured notes and loans payable to unrelated third parties ..		24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D	954,059	25	881,720
26	Total liabilities. Add lines 17 through 25..	1,722,043	26	6,057,359

	Organizations that follow FASB ASC 958, check here and complete lines 27, 28, 32, and 33.
27	Net assets without donor restrictions ..........	25,165,313	27	26,004,933
28	Net assets with donor restrictions ...........	1,698,875	28	11,107,292
	Organizations that do not follow FASB ASC 958, check here and complete lines 29 through 33.
29	Capital stock or trust principal, or current funds .....		29
30	Paid-in or capital surplus, or land, building or equipment fund ...		30
31	Retained earnings, endowment, accumulated income, or other funds		31
32	Total net assets or fund balances ...........	26,864,188	32	37,112,225
33	Total liabilities and net assets/fund balances ........	28,586,231	33	43,169,584

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to separately file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990). . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471). . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621) .	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships (see Instructions for Form 8865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990).. . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No